Report cover image

Tay-Sachs Disease Market Report and Forecast 2025-2034

Publisher Expert Market Research
Published Jul 28, 2025
Length 350 Pages
SKU # EMAR20319964

Description

The Tay-Sachs disease market size was valued at USD 2.30 Billion in 2024, driven by the rising advancements in stem cell therapies across the major markets. The market is expected to grow at a CAGR of 5.60% during the forecast period of 2025-2034, with the values likely to rise to USD 3.97 Billion by 2034.

Tay-Sachs Disease: Introduction

Tay-Sachs disease is a rare genetic condition that affects a child’s nerve cells in the brain and spinal cord. It is caused by the absence of an enzyme that helps break down fatty substances (also known as gangliosides). These substances build up to toxic levels and affect the impact the nerve cell functions. Early symptoms of the disease appear at about 3-6 months of age. The muscle development slows down and the child may experience seizures as well.

Tay-Sachs Disease Market Analysis

The Tay-Sachs disease market value is driven by the rising emphasis on mitigating the morbidities associated with the disease, which includes the development of new therapeutics and improving the existing system for improved results. AAV (adeno-associated virus) gene therapy is one of the latest therapies being investigated. It impacted the HexA activity which increased from the baseline and remained stable in patients.

In addition, there has been a significant development in other therapies as well, which includes enzyme replacement therapy, substrate reduction therapy, hematopoietic stem cell transplantation, gene therapies. The market growth is also driven by rising investments and grants for innovative treatment alternatives. The California Institute for Regenerative Medicine (CIRM) has invested a hefty sum of USD 4 million into UC Davis researchers to establish a stem cell gene therapy to treat the condition.

With a key focus on developing a genetic cure for GM2 gangliosidosis (including Tay-Sachs disease), several companies and organizations are collaborating to investigate and develop better therapies. In June 2023, New Hope Research Foundation and Forge Biologics partnered for the cGMP manufacturing to enhance the Foundation's NHR01, a novel gene therapy. Such collaborations are essential to meet the rising Tay-Sachs disease market demand and expected to boost market growth further in the coming years.

Tay-Sachs Disease Market Segmentation

Tay-Sachs Disease Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Type
  • Anticonvulsants
  • Antipsychotic Medications
  • Others
Market Breakup by Type
  • Infantile Tay - Sachs Disease
  • Juvenile Tay-Sachs Disease
  • Late-Onset Tay-Sachs Disease
Market Breakup by Treatment
  • Medication
  • Respiratory Care
  • Physical Therapy
Market Breakup by Route of Administration
  • Injectable
  • Oral
  • Others
Market Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Market Breakup by End User
  • Hospitals
  • Homecare
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  
  • Germany

    •   
  • France

    •   
  • Italy

    •   
  • Spain

    •   
  • United Kingdom
    • Japan
    Tay-Sachs Disease Market Overview

    Early screening during pregnancy is a key method to prevent genetic disorders in children. As a result, pregnancy screenings are considered highly critical nowadays. In the historical period, the condition has been more prevalent in Central and Eastern European Jewish ancestry, therefore, Europe has led the Tay-Sachs disease market share. Having a robust healthcare, along with academic institutions, there have been significant enhancements to decrease the rising burden of the disease.

    In North America, the United States is a major market with a heavy focus on disease detection at the pregnancy stage. Organizations such as JScreen have set up campaigns and have been actively encouraging people to undergo testing for genetic diseases. In the case of in-vitro fertilization, preimplantation genetic testing is widely applied.

    Asia Pacific is expected to witness exponential Tay-Sachs disease market growth, with increasing medical and research advancements occurring in the region. Mergers and acquisitions between native and international corporations is further fostering the market growth in the region. In addition, foreign investments to put the easy availability of resources to use are also impacting the market positively.

    Tay-Sachs Disease Market: Competitor Landscape

    The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
    • Recursion Pharmaceuticals, Inc.
    • IntraBioInc
    • Johnson & Johnson Services
    • Axovant Sciences, Inc.
    • Pfizer
    • Sio Gene Therapies Ltd
    • F. Hoffmann-La
    • Roche Ltd
    • Bayer AG
    • Bausch Health
    • Boehringer Ingelheim International GmbH
    Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
    *Please Note:* The report will take 5 business days to complete, after order confirmation.

    Table of Contents

    350 Pages
    1 Preface
    1.1 Objectives of the Study
    1.2 Key Assumptions
    1.3 Report Coverage – Key Segmentation and Scope
    1.4 Research Methodology
    2 Executive Summary
    3 Tay-Sachs Disease Overview
    3.1 Guidelines and Stages
    3.2 Pathophysiology
    3.3 Screening and Diagnosis
    3.4 Treatment Pathway
    4 Patient Profile
    4.1 Patient Profile Overview
    4.2 Patient Psychology and Emotional Impact Factors
    4.3 Risk Assessment and Treatment Success Rate
    5 Tay-Sachs Disease Epidemiology Analysis – 7MM
    5.1 7MM Epidemiology Scenario Overview (2018-2034)
    5.2 United States Tay-Sachs Disease Epidemiology Forecast (2018-2034)
    5.3 EU-4 and United Kingdom Tay-Sachs Disease Epidemiology Forecast (2018-2034)
    5.3.1 Germany Tay-Sachs Disease Epidemiology Forecast (2018-2034)
    5.3.2 France Tay-Sachs Disease Epidemiology Forecast (2018-2034)
    5.3.3 Italy Tay-Sachs Disease Epidemiology Forecast (2018-2034)
    5.3.4 Spain Tay-Sachs Disease Epidemiology Forecast (2018-2034)
    5.3.5 United Kingdom Tay-Sachs Disease Epidemiology Forecast (2018-2034)
    5.4 Japan Tay-Sachs Disease Epidemiology Forecast (2018-2034)
    6 Tay-Sachs Disease Market Overview – 7MM
    6.1 Tay-Sachs Disease Market Historical Value (2018-2024)
    6.2 Tay-Sachs Disease Market Forecast Value (2025-2034)
    7 Tay-Sachs Disease Market Landscape – 7MM
    7.1 Tay-Sachs Disease Developers Landscape
    7.1.1 Analysis by Year of Establishment
    7.1.2 Analysis by Company Size
    7.1.3 Analysis by Region
    7.2 Tay-Sachs Disease Product Landscape
    7.2.1 Analysis by Diseases Type
    7.2.2 Analysis by Treatments
    7.2.3 Analysis by Route of Administration
    8 Tay-Sachs Disease Challenges and Unmet Needs
    8.1 Treatment Pathway Challenges
    8.2 Compliance and Drop-Out Analysis
    8.3 Awareness and Prevention Gaps
    9 Cost of Treatment
    10 Tay-Sachs Disease Market Dynamics
    10.1 Market Drivers and Constraints
    10.2 SWOT Analysis
    10.3 Porter’s Five Forces Model
    10.4 Key Demand Indicators
    10.5 Key Price Indicators
    10.6 Industry Events, Initiatives, and Trends
    10.7 Value Chain Analysis
    11 Tay-Sachs Disease Market Segmentation – 7MM
    11.1 Tay-Sachs Disease Market by Drug Type
    11.1.1 Market Overview
    11.1.2 Anticonvulsants
    11.1.3 Antipsychotic Medications
    11.1.4 Others
    11.2 Tay-Sachs Disease Market by Type
    11.2.1 Market Overview
    11.2.2 Infantile Tay - Sachs Disease
    11.2.3 Juvenile Tay-Sachs Disease
    11.2.4 Late-Onset Tay-Sachs Disease
    11.3 Tay-Sachs Disease Market by Treatment
    11.3.1 Market Overview
    11.3.2 Medication
    11.3.3 Respiratory Care
    11.3.4 Physical Therapy
    11.4 Tay-Sachs Disease Market by Route of Administration
    11.4.1 Market Overview
    11.4.2 Injectable
    11.4.3 Oral
    11.4.4 Others
    11.5 Tay-Sachs Disease Market by Distribution Channel
    11.5.1 Market Overview
    11.5.2 Hospital Pharmacies
    11.5.3 Retail Pharmacies
    11.5.4 Online Pharmacies
    11.6 Tay-Sachs Disease Market by End User
    11.6.1 Market Overview
    11.6.2 Hospitals
    11.6.3 Homecare
    11.7 Tay-Sachs Disease Market by Region
    11.7.1 Market Overview
    11.7.2 United States
    11.7.3 EU-4 and the United Kingdom
    11.7.3.1 Germany
    11.7.3.2 France
    11.7.3.3 Italy
    11.7.3.4 Spain
    11.7.3.5 United Kingdom
    11.7.4 Japan
    12 United States Tay-Sachs Disease Market
    12.1 Tay-Sachs Disease Market Historical Value (2018-2024)
    12.2 Tay-Sachs Disease Market Forecast Value (2025-2034)
    12.3 Tay-Sachs Disease Market by Drug Type
    12.4 Tay-Sachs Disease Market by Treatment Type
    13 EU-4 and United Kingdom Tay-Sachs Disease Market
    13.1 Tay-Sachs Disease Market Historical Value (2018-2024)
    13.2 Tay-Sachs Disease Market Forecast Value (2025-2034)
    13.3 Germany Tay-Sachs Disease Market Overview
    13.3.1 Tay-Sachs Disease Market by Drug Type
    13.3.2 Tay-Sachs Disease Market by Treatment Type
    13.4 France Tay-Sachs Disease Market Overview
    13.4.1 Tay-Sachs Disease Market by Drug Type
    13.4.2 Tay-Sachs Disease Market by Treatment Type
    13.5 Italy Tay-Sachs Disease Market Overview
    13.5.1 Tay-Sachs Disease Market by Drug Type
    13.5.2 Tay-Sachs Disease Market by Treatment Type
    13.6 Spain Tay-Sachs Disease Market Overview
    13.6.1 Tay-Sachs Disease Market by Drug Type
    13.6.2 Tay-Sachs Disease Market by Treatment Type
    13.7 United Kingdom Tay-Sachs Disease Market Overview
    13.7.1 Tay-Sachs Disease Market by Drug Type
    13.7.2 Tay-Sachs Disease Market by Treatment Type
    14 Japan Tay-Sachs Disease Market
    14.1 Tay-Sachs Disease Market Historical Value (2018-2024)
    14.2 Tay-Sachs Disease Market Forecast Value (2025-2034)
    14.3 Tay-Sachs Disease Market by Drug Type
    14.4 Tay-Sachs Disease Market by Treatment Type
    15 Patent Analysis
    15.1 Analysis by Type of Patent
    15.2 Analysis by Publication year
    15.3 Analysis by Issuing Authority
    15.4 Analysis by Patent Age
    15.5 Analysis by CPC Analysis
    15.6 Analysis by Patent Valuation
    15.7 Analysis by Key Players
    16 Grants Analysis
    16.1 Analysis by year
    16.2 Analysis by Amount Awarded
    16.3 Analysis by Issuing Authority
    16.4 Analysis by Grant Application
    16.5 Analysis by Funding Institute
    16.6 Analysis by NIH Departments
    16.7 Analysis by Recipient Organization
    17 Clinical Trials Analysis
    17.1 Analysis by Trial Registration Year
    17.2 Analysis by Trial Status
    17.3 Analysis by Trial Phase
    17.4 Analysis by Therapeutic Area
    17.5 Analysis by Geography
    18 Funding and Investment Analysis
    18.1 Analysis by Funding Instances
    18.2 Analysis by Type of Funding
    18.3 Analysis by Funding Amount
    18.4 Analysis by Leading Players
    18.5 Analysis by Leading Investors
    18.6 Analysis by Geography
    19 Partnership and Collaborations Analysis
    19.1 Analysis by Partnership Instances
    19.2 Analysis by Type of Partnership
    19.3 Analysis by Leading Players
    19.4 Analysis by Geography
    20 Supplier Landscape
    20.1 Recursion Pharmaceuticals, Inc.
    20.1.1 Financial Analysis
    20.1.2 Product Portfolio
    20.1.3 Demographic Reach and Achievements
    20.1.4 Mergers and Acquisition
    20.1.5 Certifications
    20.2 IntraBioInc
    20.2.1 Financial Analysis
    20.2.2 Product Portfolio
    20.2.3 Demographic Reach and Achievements
    20.2.4 Mergers and Acquisition
    20.2.5 Certifications
    20.3 Johnson & Johnson Services
    20.3.1 Financial Analysis
    20.3.2 Product Portfolio
    20.3.3 Demographic Reach and Achievements
    20.3.4 Mergers and Acquisition
    20.3.5 Certifications
    20.4 Axovant Sciences, Inc.
    20.4.1 Financial Analysis
    20.4.2 Product Portfolio
    20.4.3 Demographic Reach and Achievements
    20.4.4 Mergers and Acquisition
    20.4.5 Certifications
    20.5 Pfizer
    20.5.1 Financial Analysis
    20.5.2 Product Portfolio
    20.5.3 Demographic Reach and Achievements
    20.5.4 Mergers and Acquisition
    20.5.5 Certifications
    20.6 Sio Gene Therapies Ltd
    20.6.1 Financial Analysis
    20.6.2 Product Portfolio
    20.6.3 Demographic Reach and Achievements
    20.6.4 Mergers and Acquisition
    20.6.5 Certifications
    20.6.6 F. Hoffmann-La
    20.7 Roche Ltd
    20.7.1 Financial Analysis
    20.7.2 Product Portfolio
    20.7.3 Demographic Reach and Achievements
    20.7.4 Mergers and Acquisition
    20.7.5 Certifications
    20.8 Bayer AG
    20.8.1 Financial Analysis
    20.8.2 Product Portfolio
    20.8.3 Demographic Reach and Achievements
    20.8.4 Mergers and Acquisition
    20.8.5 Certifications
    20.9 Bausch Health
    20.9.1 Financial Analysis
    20.9.2 Product Portfolio
    20.9.3 Demographic Reach and Achievements
    20.9.4 Mergers and Acquisition
    20.9.5 Certifications
    20.10 Boehringer Ingelheim International GmbH
    20.10.1 Financial Analysis
    20.10.2 Product Portfolio
    20.10.3 Demographic Reach and Achievements
    20.10.4 Mergers and Acquisition
    20.10.5 Certifications
    21 Tay-Sachs Disease Market - Distribution Model (Additional Insight)
    21.1 Overview
    21.2 Potential Distributors
    21.3 Key Parameters for Distribution Partner Assessment
    22 Key Opinion Leaders (KOL) Insights (Additional Insight)
    23 Company Competitiveness Analysis (Additional Insight)
    23.1 Very Small Companies
    23.2 Small Companies
    23.3 Mid-Sized Companies
    23.4 Large Companies
    23.5 Very Large Companies
    24 Payment Methods (Additional Insight)
    24.1 Government Funded
    24.2 Private Insurance
    24.3 Out-of-Pocket

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us